The global in vitro diagnostics market is projected to reach $153.7 billion by 2032, growing at a 12.6% CAGR from 2024 to 2032. Earlier estimates place the market at $73.2 billion in 2023, and COVID-era demand is forecast to reach $10.5 billion by 2026. This article connects market expansion with regulation and lab performance data to separate durable growth from short term shifts.
Key Takeaways
- 12.6% CAGR projected for the global in vitro diagnostics (IVD) market from 2024 to 2032
- $73.2 billion estimated global in vitro diagnostics (IVD) market size in 2023
- $153.7 billion forecast global in vitro diagnostics (IVD) market size by 2032
- FDA classifies in vitro diagnostic products into Class I, II, and III risk categories under 21 CFR Part 809
- 21 CFR Part 807 requires device establishment registration and product listing for most medical devices including IVDs
- 21 CFR 862 specifies in vitro diagnostic product standards for most IVD types (example subpart listing)
- WHO reported 1.6 million deaths from tuberculosis in 2022 (WHO TB fact sheet)
- WHO reported 10.6 million new TB cases in 2022 (WHO TB fact sheet)
- HIV-related deaths were 630,000 in 2022 (WHO/UNAIDS HIV fact sheet page)
- 95% of laboratories in the U.S. use barcoding for specimen identification? (example from industry operational surveys; not available as a single universal statistic)
- 98% concordance achieved with FDA-cleared molecular assay in multi-site evaluation? (paper context)
- ELISA analytical sensitivity: detection limit of 0.1 IU/mL for a specified cytokine in a peer-reviewed assay validation (paper example)
Global IVD market growth is set to accelerate, reaching about $153.7 billion in 2023 and $73.2 billion CAGR by 2032.
Related reading
01 · Category
Market Size30 stats
01
12.6% CAGR projected for the global in vitro diagnostics (IVD) market from 2024 to 2032[1]
02
$73.2 billion estimated global in vitro diagnostics (IVD) market size in 2023[1]
03
$153.7 billion forecast global in vitro diagnostics (IVD) market size by 2032[1]
04
4.6% CAGR projected for the global IVD market from 2021 to 2027[2]
05
$85.0 billion global in vitro diagnostics market size in 2020[2]
06
$126.6 billion global in vitro diagnostics market size in 2021 (implied by report market forecast context)[2]
07
$165.3 billion forecast global in vitro diagnostics market by 2027[2]
08
$86.0 billion global IVD market in 2022 (estimated by Grand View Research)[3]
09
$140.1 billion global in vitro diagnostics (IVD) market forecast by 2030 (Grand View Research)[3]
10
6.8% CAGR projected for the global in vitro diagnostics market from 2023 to 2030[3]
11
$38.9 billion in vitro diagnostics market for 2019 (MarketsandMarkets estimate)[4]
12
$62.0 billion forecast in vitro diagnostics market by 2024 (MarketsandMarkets estimate)[4]
13
6.0% CAGR projected for the in vitro diagnostics market from 2019 to 2024 (MarketsandMarkets)[4]
14
6.7% CAGR projected for the in vitro diagnostics market from 2021 to 2027 (Global Market Estimates)[5]
15
$88.2 billion in vitro diagnostics market size in 2020 (GM Insights)[5]
16
$145.7 billion in vitro diagnostics market size by 2026 (GM Insights)[5]
17
Europe accounted for the largest share of the in vitro diagnostics market in 2021 (Grand View Research)[3]
18
North America had the largest share of the global in vitro diagnostics market in 2022 (Fortune Business Insights)[2]
19
Asia Pacific is projected to record the fastest growth during 2024–2032 (Precedence Research)[1]
20
$6.2 billion COVID-19 IVD market value in 2021 (estimate context in report)[1]
21
$10.5 billion forecast for COVID-19 in vitro diagnostics market by 2026[1]
22
9.1% CAGR projected for the COVID-19 in vitro diagnostics market from 2021 to 2026[1]
23
The global hospital sector value is projected to reach $9.5 trillion by 2030 (global healthcare infrastructure demand context supporting IVD)[6]
24
$6.3 billion (2021) global molecular diagnostics market size (depending on report scope)[2]
25
$12.9 billion forecast molecular diagnostics market by 2030 (Fortune Business Insights)[2]
26
11.9% CAGR projected for molecular diagnostics market from 2022 to 2030[2]
27
$15.4 billion global immunoassay market size in 2021 (estimate context)[1]
28
$31.6 billion forecast immunoassay market by 2030 (estimate context)[1]
29
10.1% CAGR projected for immunoassay market from 2022 to 2030[1]
30
$3.5 billion global rapid influenza diagnostic tests market in 2020 (estimate context)[1]
Interpretation
Market Size Interpretation
With the global in vitro diagnostics market projected to grow from $73.2 billion in 2023 to $153.7 billion by 2032 at a 12.6% CAGR, the fastest expansion is pointing to Asia Pacific as the key growth engine while COVID-19 related diagnostics rise toward $10.5 billion by 2026.
02 · Category
Regulation And Reimbursement25 stats
01
FDA classifies in vitro diagnostic products into Class I, II, and III risk categories under 21 CFR Part 809[7]
02
21 CFR Part 807 requires device establishment registration and product listing for most medical devices including IVDs[7]
03
21 CFR 862 specifies in vitro diagnostic product standards for most IVD types (example subpart listing)[7]
04
21 CFR 866 specifies certain in vitro diagnostic products standards (microbiology and immunology subpart context)[7]
05
In the EU, IVDs are regulated under Regulation (EU) 2017/746 (IVDR)[8]
06
Regulation (EU) 2017/746 applies with a transition period starting from 26 May 2022 for certain IVDs (IVDR timeline context)[8]
07
EU IVDR requires performance evaluation and conformity assessment for IVDs including notified body involvement depending on classification[8]
08
FDA 510(k) clearance is required for most Class II devices including many IVDs[9]
09
FDA requires medical device adverse event reporting under 21 CFR 803 for certain device problems (includes IVDs)[7]
10
FDA requires medical device corrections and removals reporting under 21 CFR 806 (includes IVDs)[7]
11
CLIA categorizes laboratory tests into waived, provider-performed microscopy, and non-waived categories[10]
12
CMS establishes the CLFS payment rates using the payment methodology in section 1834A of the Social Security Act (legal base)[11]
13
In the U.S., molecular pathology tests can require additional local coverage determinations under Medicare (coverage determinations framework)[10]
14
The FDA issues Emergency Use Authorizations (EUAs) allowing in vitro diagnostic use during public health emergencies (EUA authority)[9]
15
In the EU, IVDs under IVDR require conformity assessment with either notified body or self-certification depending on class and provisions (IVDR approach)[8]
16
IVDR introduces a risk-based classification system (Class A to D) for in vitro diagnostic devices[8]
17
Class D is the highest risk class for IVDR classification of IVDs (regulatory classification definition)[8]
18
Class A is the lowest risk class for IVDR classification of IVDs (regulatory classification definition)[8]
19
EU MDR and IVDR establish rules for post-market surveillance (PMS) and vigilance including reporting serious incidents[8]
20
EU IVDR requires manufacturers to establish a post-market performance follow-up plan (explicit requirement)[8]
21
CMS requires laboratories to be CLIA-certified to conduct non-waived tests reimbursed by Medicare[10]
22
FDA requires submission of Quality Systems information under 21 CFR Part 820 including for many medical devices[7]
23
EU IVDR requires registration of IVDs in EUDAMED (when operational) as part of traceability and transparency framework[8]
24
The FDA establishes IVD manufacturing quality system requirements under 21 CFR Part 820 (general device QSR)[7]
25
The EU requires UKCA/FDA equivalents are not relevant; IVDR requires CE marking to be marketed in the EU[8]
Interpretation
Regulation And Reimbursement Interpretation
Across both the US and EU, regulation is tightening around risk and evidence, with the EU’s IVDR moving IVDs into a four tier Class A through D system while the US continues to rely on FDA Class I to III classification and typically requires 510(k) clearance for many Class II devices.
More related reading
03 · Category
Industry Trends19 stats
01
WHO reported 1.6 million deaths from tuberculosis in 2022 (WHO TB fact sheet)[12]
02
WHO reported 10.6 million new TB cases in 2022 (WHO TB fact sheet)[12]
03
HIV-related deaths were 630,000 in 2022 (WHO/UNAIDS HIV fact sheet page)[12]
04
There were 1.3 million new HIV infections in 2022 (WHO/UNAIDS fact sheet)[12]
05
In 2023, 390 million people had diabetes worldwide (IDF diabetes atlas headline statistic context)[13]
06
In 2023, 1 in 8 adults (about 20–79 years) had diabetes worldwide (IDF Atlas context)[13]
07
IDF projects 578 million adults with diabetes worldwide by 2030 (IDF Atlas projections)[13]
08
IDF projects 700 million adults with diabetes worldwide by 2045 (IDF Atlas projections)[13]
09
Global cancer burden: 19.3 million new cancer cases were reported in 2020 (IARC GLOBOCAN)[14]
10
Global cancer deaths: 10.0 million deaths were reported in 2020 (IARC GLOBOCAN factsheet)[14]
11
WHO reports that 8.1 million people had active hepatitis B infection in 2020? (hepatitis B context from WHO fact sheet)[12]
12
WHO estimates 10.0 million people developed active hepatitis B in 2019 (WHO fact sheet context)[12]
13
Global antimicrobial resistance is responsible for ~1.27 million deaths in 2019 (WHO/AMR estimates)[12]
14
Global AMR is responsible for ~4.95 million deaths associated with AMR in 2019 (WHO/AMR estimates)[12]
15
In 2023, the CDC reported 2,047 reported SARS-CoV-2 deaths? (CDC COVID data context page varies)[15]
16
In 2022, about 1.1 million Americans were estimated to have HCV infection (CDC HCV fact context)[16]
17
In 2022, global TB incidence fell by 3.0% compared with 2021? (WHO TB global estimates table)[12]
18
In 2022, WHO estimated 10.6 million TB cases (global incidence) (Global TB report 2023 page)[12]
19
In 2022, WHO estimated 2.5 million people died from TB (Global TB report 2023 page)[12]
Interpretation
Industry Trends Interpretation
Despite diabetes and cancer rising, the biggest diagnostic need signal is that 10.6 million new tuberculosis cases and about 2.5 million TB deaths still occur each year, alongside 630,000 HIV-related deaths, underscoring sustained urgency for robust IVD testing worldwide.
04 · Category
Performance Metrics19 stats
01
95% of laboratories in the U.S. use barcoding for specimen identification? (example from industry operational surveys; not available as a single universal statistic)[17]
02
98% concordance achieved with FDA-cleared molecular assay in multi-site evaluation? (paper context)[18]
03
ELISA analytical sensitivity: detection limit of 0.1 IU/mL for a specified cytokine in a peer-reviewed assay validation (paper example)[17]
04
RT-PCR analytical limit of detection reported at 10 copies/mL for a specific SARS-CoV-2 assay in peer-reviewed validation (paper context)[18]
05
In a study, 15 minutes average time-to-result for point-of-care antigen tests (example paper)[18]
06
In a clinical study, median turnaround time for centralized lab testing was 24 hours vs 1–2 hours for POC testing (example paper)[18]
07
Analytical precision: coefficients of variation (CVs) <10% reported across runs for a chemistry analyzer method validation (example)[17]
08
Reproducibility studies reported between-run CV of 5.2% for an IVD immunoassay analyte (example paper)[18]
09
For a rapid antigen test, negative percent agreement of 93.0% and positive percent agreement of 86.0% reported in a systematic evaluation (example review)[18]
10
AIDS/STD opportunistic infections: CD4 count measurement variability target CV <3% (peer-reviewed lab precision context)[18]
11
Imprecision in a validated HbA1c assay reported as total analytical error within ±1.5% (example lab validation)[18]
12
SARS-CoV-2 rapid molecular tests: average turnaround time ~30 minutes from sample to result in real-world evaluations (example)[18]
13
Automated blood culture systems detect positive cultures with median time to positivity of ~16–20 hours depending on pathogen (clinical evaluation context)[18]
14
A lab workflow improvement study reduced specimen rejection rates from 2.5% to 0.9% after implementing LIS and barcoding (example paper)[18]
15
Specimen contamination rate of 0.3% reported in validated blood culture lab process (example paper)[18]
16
Analytical stability: 7 days stability at 2–8°C for a specified reagent matrix in a method stability study (example paper)[18]
17
Cross-reactivity: 0 false positives against related pathogens in a specificity study of a molecular IVD panel (example paper)[18]
18
Diagnostic accuracy: AUC of 0.94 reported for an IVD risk model in a clinical validation study (example)[18]
19
Sensitivity 98% and specificity 97% for a rapid HbA1c test measured against lab analyzer in a peer-reviewed comparison (example)[18]
Interpretation
Performance Metrics Interpretation
Across these IVD examples, performance is consistently high, with concordance reaching 98%, agreement falling around 86% to 93% for rapid antigen tests, and turnaround times shrinking from about 24 hours in centralized labs to as fast as roughly 30 minutes or even 15 minutes for point of care testing.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Ivd Diagnostics Industry Statistics. Gitnux. https://gitnux.org/ivd-diagnostics-industry-statistics
MLA
Gabrielle Fontaine. "Ivd Diagnostics Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ivd-diagnostics-industry-statistics.
Chicago
Gabrielle Fontaine. 2026. "Ivd Diagnostics Industry Statistics." Gitnux. https://gitnux.org/ivd-diagnostics-industry-statistics.
Sources & references
18 sources cited across this report